{"id":{"repo_id":"uiuc","oai_identifier":"oai:www.ideals.illinois.edu:2142/110792"},"canonical_url":"https://search.dev.ndltd.org/etd/uiuc/oai:www.ideals.illinois.edu:2142/110792","repository":{"repo_id":"uiuc","name":"University of Illinois - Urbana-Champaign","base_url":"https://www.ideals.illinois.edu/oai-pmh"},"display":{"title":"Optimizing pharmacodynamics and evaluating echocardiographic effects of alfaxalone sedation in bearded dragons (Pogona vitticeps) and prairie rattlesnakes (Crotalus viridis)","abstract":"Alfaxalone, a neurogenic steroid with action at the γ-aminobutyric acid A receptor, is an injectable sedative frequently utilized in squamate medicine. A novel formulation of alfaxalone was recently approved by the Food and Drug Administration for 28-day use after breaching the vial due to the addition of proprietary preservatives. Previous research performed in squamates focuses on evaluating one route of administration at one or more doses and monitoring the effects of alfaxalone on that species (i.e. heart rate, respiratory rate, depth of sedation (Bertelsen 2011, Ferreira 2019, James 2018, Strahl-Heldreth 2019, Jurox 2020, Perrin 2017, Scheelings 2011). This thesis research examines the use of the new formulation of alfaxalone in two species: the bearded dragon and the prairie rattlesnake. Bearded dragons (Pogona vitticeps), a popular zoological companion species, frequently require sedation for procedures. Prairie rattlesnakes (Crotalus viridis) act as a model for that species and other Viperidae housed in zoological institutions or studied in free-ranging populations that require sedation to facilitate safe handling, examination, and minimally invasive procedures. A group of bearded dragons (n=10) and prairie rattlesnakes (n=10) were respectively sedated with alfaxalone at 15 mg/kg and 20 mg/kg based on a pilot study that identified the optimal dose for each species. A complete cross-over design evaluated four routes of administration: intracoelomic, subcutaneous, intramuscular, and intravenous. The optimal route of administration, defined as the route that provided consistent deep sedation with loss of righting reflex, maintenance of spontaneous respiration, and a clinically normal heart rate, was identified as intravenous (coccygeal vein) in bearded dragons and intramuscular (epaxials cranial to the heart) in prairie rattlesnakes. Echocardiography evaluated whether the cardiac function of either species was significantly affected by alfaxalone administered at the optimal dose and route of administration. End systolic volume was the only echocardiographic parameter that significantly increased in bearded dragons indicating a decrease in cardiac contractility secondary to sedation. Prairie rattlesnake echocardiographic values were not affected. Administration of alfaxalone at 15 mg/kg intravenously in the coccygeal vein of bearded dragons and 20 mg/kg intramuscularly in the cranial epaxials of prairie rattlesnakes should facilitate safe handling and immobilization for minimally invasive procedures in each species.","abstract_html":"Alfaxalone, a neurogenic steroid with action at the γ-aminobutyric acid A receptor, is an injectable sedative frequently utilized in squamate medicine. A novel formulation of alfaxalone was recently approved by the Food and Drug Administration for 28-day use after breaching the vial due to the addition of proprietary preservatives. Previous research performed in squamates focuses on evaluating one route of administration at one or more doses and monitoring the effects of alfaxalone on that species (i.e. heart rate, respiratory rate, depth of sedation (Bertelsen 2011, Ferreira 2019, James 2018, Strahl-Heldreth 2019, Jurox 2020, Perrin 2017, Scheelings 2011). This thesis research examines the use of the new formulation of alfaxalone in two species: the bearded dragon and the prairie rattlesnake. Bearded dragons (Pogona vitticeps), a popular zoological companion species, frequently require sedation for procedures. Prairie rattlesnakes (Crotalus viridis) act as a model for that species and other Viperidae housed in zoological institutions or studied in free-ranging populations that require sedation to facilitate safe handling, examination, and minimally invasive procedures. A group of bearded dragons (n=10) and prairie rattlesnakes (n=10) were respectively sedated with alfaxalone at 15 mg/kg and 20 mg/kg based on a pilot study that identified the optimal dose for each species. A complete cross-over design evaluated four routes of administration: intracoelomic, subcutaneous, intramuscular, and intravenous. The optimal route of administration, defined as the route that provided consistent deep sedation with loss of righting reflex, maintenance of spontaneous respiration, and a clinically normal heart rate, was identified as intravenous (coccygeal vein) in bearded dragons and intramuscular (epaxials cranial to the heart) in prairie rattlesnakes. Echocardiography evaluated whether the cardiac function of either species was significantly affected by alfaxalone administered at the optimal dose and route of administration. End systolic volume was the only echocardiographic parameter that significantly increased in bearded dragons indicating a decrease in cardiac contractility secondary to sedation. Prairie rattlesnake echocardiographic values were not affected. Administration of alfaxalone at 15 mg/kg intravenously in the coccygeal vein of bearded dragons and 20 mg/kg intramuscularly in the cranial epaxials of prairie rattlesnakes should facilitate safe handling and immobilization for minimally invasive procedures in each species.","abstract_has_math":false,"creators":["Webb, Joanna K."],"institution":"University of Illinois at Urbana-Champaign","degree_name":"M.S.","degree_level":"Thesis","degree_discipline":"VMS-Veterinary Clinical Medcne","degree_department":null,"school":null,"contributors":["Keller, Krista A","Allender, Matthew C","Fries, Ryan C","Chinnadurai, Sathya K"],"advisors":[],"committee_chairs":[],"committee_members":[],"year":2021,"date_issued":"2021-09-17T04:04:07Z","date_published":"2021-09-17T04:04:07Z","updated_at":"2026-07-22T22:24:52Z","subjects":["alfaxalone, squamate, bearded dragon, prairie rattlesnake, echocardiography"],"languages":["en"],"rights":["2021 Joanna K. Webb"],"rights_urls":[],"identifier_entries":[]},"links":{"outbound_url":"http://hdl.handle.net/2142/110792","outbound_label":"Handle","outbound_source":"dc:identifier"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor","label":"Contributor","values":["Keller, Krista A","Allender, Matthew C","Fries, Ryan C","Chinnadurai, Sathya K"]},{"key":"dc:creator","label":"Author","values":["Webb, Joanna K."]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date","label":"Dc Date","values":["2021-09-17T04:04:07Z","2023-09-17T04:07:01Z","2021-04-07","2021-05"]},{"key":"dc:type","label":"Dc Type","values":["text","Thesis"]},{"key":"thesis:degree_discipline","label":"Discipline","values":["VMS-Veterinary Clinical Medcne"]},{"key":"thesis:degree_level","label":"Degree Level","values":["Thesis"]},{"key":"thesis:degree_name","label":"Degree Name","values":["M.S."]},{"key":"thesis:institution_name","label":"Thesis Institution Name","values":["University of Illinois at Urbana-Champaign"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["alfaxalone, squamate, bearded dragon, prairie rattlesnake, echocardiography"]}]},{"id":"language_rights","label":"Language and Rights","entries":[{"key":"dc:language","label":"Dc Language","values":["en"]},{"key":"dc:rights","label":"Dc Rights","values":["2021 Joanna K. Webb"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier","label":"Identifier","values":["http://hdl.handle.net/2142/110792"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description","label":"Description","values":["Alfaxalone, a neurogenic steroid with action at the γ-aminobutyric acid A receptor, is an injectable sedative frequently utilized in squamate medicine. A novel formulation of alfaxalone was recently approved by the Food and Drug Administration for 28-day use after breaching the vial due to the addition of proprietary preservatives. Previous research performed in squamates focuses on evaluating one route of administration at one or more doses and monitoring the effects of alfaxalone on that species (i.e. heart rate, respiratory rate, depth of sedation (Bertelsen 2011, Ferreira 2019, James 2018, Strahl-Heldreth 2019, Jurox 2020, Perrin 2017, Scheelings 2011). This thesis research examines the use of the new formulation of alfaxalone in two species: the bearded dragon and the prairie rattlesnake. Bearded dragons (Pogona vitticeps), a popular zoological companion species, frequently require sedation for procedures. Prairie rattlesnakes (Crotalus viridis) act as a model for that species and other Viperidae housed in zoological institutions or studied in free-ranging populations that require sedation to facilitate safe handling, examination, and minimally invasive procedures. A group of bearded dragons (n=10) and prairie rattlesnakes (n=10) were respectively sedated with alfaxalone at 15 mg/kg and 20 mg/kg based on a pilot study that identified the optimal dose for each species. A complete cross-over design evaluated four routes of administration: intracoelomic, subcutaneous, intramuscular, and intravenous. The optimal route of administration, defined as the route that provided consistent deep sedation with loss of righting reflex, maintenance of spontaneous respiration, and a clinically normal heart rate, was identified as intravenous (coccygeal vein) in bearded dragons and intramuscular (epaxials cranial to the heart) in prairie rattlesnakes. Echocardiography evaluated whether the cardiac function of either species was significantly affected by alfaxalone administered at the optimal dose and route of administration. End systolic volume was the only echocardiographic parameter that significantly increased in bearded dragons indicating a decrease in cardiac contractility secondary to sedation. Prairie rattlesnake echocardiographic values were not affected. Administration of alfaxalone at 15 mg/kg intravenously in the coccygeal vein of bearded dragons and 20 mg/kg intramuscularly in the cranial epaxials of prairie rattlesnakes should facilitate safe handling and immobilization for minimally invasive procedures in each species.","Submission published under a 24 month embargo labeled 'Closed Access', the embargo will last until 2023-05-01","The student, Joanna Webb, accepted the attached license on 2021-04-02 at 08:20.","The student, Joanna Webb, submitted this Thesis for approval on 2021-04-02 at 08:37.","This Thesis was approved for publication on 2021-04-07 at 16:39.","DSpace SAF Submission Ingestion Package generated from Vireo submission #16230 on 2021-09-16 at 20:08:00","Made available in DSpace on 2021-09-17T04:04:07Z (GMT). No. of bitstreams: 2 WEBB-THESIS-2021.pdf: 1505114 bytes, checksum: 1e75c03ebf3cdd00207595fd48797901 (MD5) LICENSE.txt: 4208 bytes, checksum: d722ce52744f239d84e2c1653cb44883 (MD5) Previous issue date: 2021-04-07","Embargo set by: Seth Robbins for item 118637 Lift date: 2023-09-17T04:04:53Z Reason: Author requested closed access (OA after 2yrs) in Vireo ETD system","Embargo set by: Seth Robbins for item 118637 Lift date: 2023-09-17T04:07:01Z Reason: Author requested closed access (OA after 2yrs) in Vireo ETD system","Author requested closed access (OA after 2yrs) in Vireo ETD system","Limited"]},{"key":"dc:format","label":"Dc Format","values":["application/pdf"]},{"key":"dc:title","label":"Title","values":["Optimizing pharmacodynamics and evaluating echocardiographic effects of alfaxalone sedation in bearded dragons (Pogona vitticeps) and prairie rattlesnakes (Crotalus viridis)"]}]}],"canonical_facts":{"dc:contributor":["Keller, Krista A","Allender, Matthew C","Fries, Ryan C","Chinnadurai, Sathya K"],"dc:creator":["Webb, Joanna K."],"dc:date":["2021-09-17T04:04:07Z","2023-09-17T04:07:01Z","2021-04-07","2021-05"],"dc:description":["Alfaxalone, a neurogenic steroid with action at the γ-aminobutyric acid A receptor, is an injectable sedative frequently utilized in squamate medicine. A novel formulation of alfaxalone was recently approved by the Food and Drug Administration for 28-day use after breaching the vial due to the addition of proprietary preservatives. Previous research performed in squamates focuses on evaluating one route of administration at one or more doses and monitoring the effects of alfaxalone on that species (i.e. heart rate, respiratory rate, depth of sedation (Bertelsen 2011, Ferreira 2019, James 2018, Strahl-Heldreth 2019, Jurox 2020, Perrin 2017, Scheelings 2011). This thesis research examines the use of the new formulation of alfaxalone in two species: the bearded dragon and the prairie rattlesnake. Bearded dragons (Pogona vitticeps), a popular zoological companion species, frequently require sedation for procedures. Prairie rattlesnakes (Crotalus viridis) act as a model for that species and other Viperidae housed in zoological institutions or studied in free-ranging populations that require sedation to facilitate safe handling, examination, and minimally invasive procedures. A group of bearded dragons (n=10) and prairie rattlesnakes (n=10) were respectively sedated with alfaxalone at 15 mg/kg and 20 mg/kg based on a pilot study that identified the optimal dose for each species. A complete cross-over design evaluated four routes of administration: intracoelomic, subcutaneous, intramuscular, and intravenous. The optimal route of administration, defined as the route that provided consistent deep sedation with loss of righting reflex, maintenance of spontaneous respiration, and a clinically normal heart rate, was identified as intravenous (coccygeal vein) in bearded dragons and intramuscular (epaxials cranial to the heart) in prairie rattlesnakes. Echocardiography evaluated whether the cardiac function of either species was significantly affected by alfaxalone administered at the optimal dose and route of administration. End systolic volume was the only echocardiographic parameter that significantly increased in bearded dragons indicating a decrease in cardiac contractility secondary to sedation. Prairie rattlesnake echocardiographic values were not affected. Administration of alfaxalone at 15 mg/kg intravenously in the coccygeal vein of bearded dragons and 20 mg/kg intramuscularly in the cranial epaxials of prairie rattlesnakes should facilitate safe handling and immobilization for minimally invasive procedures in each species.","Submission published under a 24 month embargo labeled 'Closed Access', the embargo will last until 2023-05-01","The student, Joanna Webb, accepted the attached license on 2021-04-02 at 08:20.","The student, Joanna Webb, submitted this Thesis for approval on 2021-04-02 at 08:37.","This Thesis was approved for publication on 2021-04-07 at 16:39.","DSpace SAF Submission Ingestion Package generated from Vireo submission #16230 on 2021-09-16 at 20:08:00","Made available in DSpace on 2021-09-17T04:04:07Z (GMT). No. of bitstreams: 2 WEBB-THESIS-2021.pdf: 1505114 bytes, checksum: 1e75c03ebf3cdd00207595fd48797901 (MD5) LICENSE.txt: 4208 bytes, checksum: d722ce52744f239d84e2c1653cb44883 (MD5) Previous issue date: 2021-04-07","Embargo set by: Seth Robbins for item 118637 Lift date: 2023-09-17T04:04:53Z Reason: Author requested closed access (OA after 2yrs) in Vireo ETD system","Embargo set by: Seth Robbins for item 118637 Lift date: 2023-09-17T04:07:01Z Reason: Author requested closed access (OA after 2yrs) in Vireo ETD system","Author requested closed access (OA after 2yrs) in Vireo ETD system","Limited"],"dc:format":["application/pdf"],"dc:identifier":["http://hdl.handle.net/2142/110792"],"dc:language":["en"],"dc:rights":["2021 Joanna K. Webb"],"dc:subject":["alfaxalone, squamate, bearded dragon, prairie rattlesnake, echocardiography"],"dc:title":["Optimizing pharmacodynamics and evaluating echocardiographic effects of alfaxalone sedation in bearded dragons (Pogona vitticeps) and prairie rattlesnakes (Crotalus viridis)"],"dc:type":["text","Thesis"],"thesis:degree_discipline":["VMS-Veterinary Clinical Medcne"],"thesis:degree_level":["Thesis"],"thesis:degree_name":["M.S."],"thesis:institution_name":["University of Illinois at Urbana-Champaign"]},"updated_at":"2026-07-22T22:24:52Z"}